Britain's GW Pharmaceuticals Plc (GWP.L: Quote) said on Tuesday its pioneering cannabis-based drug Sativex had qualified to be considered for approval by Canadian regulators as a treatment for cancer pain.

"We are delighted to receive this Qualifying Notice from Health Canada and look forward to receiving regulatory approval for Sativex in the relief of cancer pain in the next few months," Chairman Geoffrey Guy said in a statement.

Sativex is an under-the-tongue spray which is already on sale in Canada as a treatment for pain in multiple sclerosis.

GW said the Qualifying Notice confirmed that Sativex qualified to be considered for approval in cancer pain and set out the conditions and post-approval undertakings upon which the marketing authorization in this indication could be granted.

GW is required to respond and accept the conditions within 30 days. Following this, Health Canada will review this response, subject to a 30-day review target. Should the response be acceptable, Health Canada can then be expected to proceed to finalize the marketing authorization.

GW also announced a net loss of 6.7 million pounds ($13.3 million) for the six months to March 31 after a loss of 6.9 million last year.

Shares in GW closed at 88 pence on Monday, valuing the firm at 105.6 million pounds.

http://ca.today.reuters.com  

TrackBack URI for this entry

Comments (0)

Subscribe to this comment's feed

Show/Hide comments

Show/Hide comment form